Freestone Grove Partners LP Arcutis Biotherapeutics, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 35,818 shares of ARQT stock, worth $448,083. This represents 0.01% of its overall portfolio holdings.
Number of Shares
35,818Holding current value
$448,083% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
217Shares Held
129MCall Options Held
2.02MPut Options Held
202K-
Jennison Associates LLC12.3MShares$154 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$143 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$137 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$110 Million7.34% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$108 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $753M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...